Future investigations should utilize genetically engineered mouse models (GEMMs) that better mimic key molecular subtypes of human NSCLC (e.g., KRAS-driven or KRAS/p53-mutant models (77)) to validate our findings in more clinically relevant settings. Here, KRAS is linked to non-small cell lung carcinoma.